MILabs’ VECTor6 with groundbreaking PET performance awarded Innovation of the Year at the WMIC 2018

MILabs’ VECTor6 with groundbreaking PET performance awarded Innovation of the Year at the WMIC 2018

15 September 2018, Utrecht, The Netherlands – MILabs is pleased to announce that its new VECTor6 with Broadband Photon Tomography technique has received the Commercial Innovation Award at the World Molecular Imaging Congress (WMIC) in Seattle September 12th-15th, 2018.

Cristal Therapeutics initiates phase 2 clinical trial with CriPec docetaxel in ovarian cancer

Cristal Therapeutics initiates phase 2 clinical trial with CriPec docetaxel in ovarian cancer

25 October 2018 , Maastricht, The Netherlands – Cristal Therapeutics, a clinical stage pharmaceutical company developing unique nanomedicines for the treatment of cancer and other diseases, announced today the first patient has been dosed in its Phase 2 clinical trial of lead nanomedicine candidate CPC634 for patients with platinum-resistant ovarian cancer.

Cristal Therapeutics appoints Dr. Axel Mescheder as CEO and CMO

Cristal Therapeutics appoints Dr. Axel Mescheder as CEO and CMO

2 November 2018, Maastricht, The Netherlands – Cristal Therapeutics has appointed Dr. Axel Mescheder to the role of Chief Executive Officer (CEO) with immediate effect. He will also serve as Chief Medical Officer (CMO).